Literature DB >> 10823861

Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein.

D J Schofield1, J Glamann, S U Emerson, R H Purcell.   

Abstract

Two monoclonal antibodies (MAbs) against the ORF2 protein of the SAR-55 strain of hepatitis E virus (HEV) were isolated by phage display from a cDNA library of chimpanzee (Pan troglodytes) gamma1/kappa antibody genes. Both MAbs, HEV#4 and HEV#31, bound to reduced, denatured open reading frame 2 (ORF2) protein in a Western blot, suggesting that they recognize linear epitopes. The affinities (equilibrium dissociation constants, K(d)) for the SAR-55 ORF2 protein were 1.7 nM for HEV#4 and 5.4 nM for HEV#31. The two MAbs also reacted in an enzyme-linked immunosorbent assay with recombinant ORF2 protein from a heterologous HEV, the Meng strain. Each MAb blocked the subsequent binding of the other MAb to homologous ORF2 protein in indirect competition assays, suggesting that they recognize the same or overlapping epitopes. Radioimmunoprecipitation assays suggested that at least part of the linear epitope(s) recognized by the two MAbs is located between amino acids 578 and 607. MAbs were mixed with homologous HEV in vitro and then inoculated into rhesus monkeys (Macaca mulatta) to determine their neutralizing ability. Whereas all control animals developed hepatitis (elevated liver enzyme levels in serum) and seroconverted to HEV, those receiving an inoculum incubated with either HEV#4 or HEV#31 were not infected. Therefore, each MAb neutralized the SAR-55 strain of HEV in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823861      PMCID: PMC112041          DOI: 10.1128/jvi.74.12.5548-5555.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  A novel virus in swine is closely related to the human hepatitis E virus.

Authors:  X J Meng; R H Purcell; P G Halbur; J R Lehman; D M Webb; T S Tsareva; J S Haynes; B J Thacker; S U Emerson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.

Authors:  S A Tsarev; T S Tsareva; S U Emerson; S Govindarajan; M Shapiro; J L Gerin; R H Purcell
Journal:  Vaccine       Date:  1997-12       Impact factor: 3.641

3.  Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in Northern California.

Authors:  E E Mast; I K Kuramoto; M O Favorov; V R Schoening; B T Burkholder; C N Shapiro; P V Holland
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries.

Authors:  H J Ditzel; P W Parren; J M Binley; J Sodroski; J P Moore; C F Barbas; D R Burton
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

6.  Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.

Authors:  J Glamann; D R Burton; P W Parren; H J Ditzel; K A Kent; C Arnold; D Montefiori; V M Hirsch
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Seroreactivity to hepatitis E virus in areas where the disease is not endemic.

Authors:  D L Thomas; P O Yarbough; D Vlahov; S A Tsarev; K E Nelson; A J Saah; R H Purcell
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

8.  Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.

Authors:  J Thompson; T Pope; J S Tung; C Chan; G Hollis; G Mark; K S Johnson
Journal:  J Mol Biol       Date:  1996-02-16       Impact factor: 5.469

9.  Antibodies against hepatitis E virus in Old World monkeys.

Authors:  V A Arankalle; M K Goverdhan; K Banerjee
Journal:  J Viral Hepat       Date:  1994       Impact factor: 3.728

10.  Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance.

Authors:  D J Schofield; N J Dimmock
Journal:  J Virol Methods       Date:  1996-10       Impact factor: 2.014

View more
  53 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro.

Authors:  Suzanne U Emerson; Hanh Nguyen; Udana Torian; Robert H Purcell
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

3.  Gene expression profiles of T cells from hepatitis E virus infected patients in acute and resolving phase.

Authors:  Nirupma TrehanPati; Sukriti Sukriti; Robert Geffers; Syed Hissar; Peggy Riese; Tanja Toepfer; Carlos A Guzman; Shiv Kumar Sarin
Journal:  J Clin Immunol       Date:  2011-02-03       Impact factor: 8.317

4.  In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons.

Authors:  Judith Graff; Hanh Nguyen; Chaiyan Kasorndorkbua; Patrick G Halbur; Marisa St Claire; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

6.  Hepatitis E vaccine.

Authors:  Rakesh Aggarwal; Shahid Jameel
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

7.  Prevention of Viral Hepatitis.

Authors:  Raymond S. Koff
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

8.  Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.

Authors:  Osmany Larralde; Juraj Petrik
Journal:  Med Microbiol Immunol       Date:  2017-04-22       Impact factor: 3.402

Review 9.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

10.  Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.

Authors:  Ruhe Men; Tetsu Yamashiro; Ana P Goncalvez; Claire Wernly; Darren J Schofield; Suzanne U Emerson; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.